AR103645A1 - USE OF A FORMALDEHYDE CLEANER IN A PHARMACEUTICAL COMPOSITION - Google Patents

USE OF A FORMALDEHYDE CLEANER IN A PHARMACEUTICAL COMPOSITION

Info

Publication number
AR103645A1
AR103645A1 ARP160100355A ARP160100355A AR103645A1 AR 103645 A1 AR103645 A1 AR 103645A1 AR P160100355 A ARP160100355 A AR P160100355A AR P160100355 A ARP160100355 A AR P160100355A AR 103645 A1 AR103645 A1 AR 103645A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
formaldehyde
compositions
formaldehyde cleaner
treatment
Prior art date
Application number
ARP160100355A
Other languages
Spanish (es)
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of AR103645A1 publication Critical patent/AR103645A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas que comprenden N-(3,5-dimetoxifenil)-N-(1-metiletil)-N-[3-(1-metil-1H-pirazol-4-i)quinoxalin-6-il]etan-1,2-diamina, o una sal farmacéuticamente aceptable de la misma o un solvato de la misma. Procesos para la preparación de dichas composiciones. Uso de dichas composiciones para la manufactura de un medicamento para la profilaxis de, o el tratamiento, en particular el tratamiento, de enfermedades, por ej. cáncer. Reivindicación 3: El uso de acuerdo con la reivindicación 1 ó 2, donde el depurador de formaldehído es meglumina.Pharmaceutical compositions comprising N- (3,5-dimethoxyphenyl) -N- (1-methylethyl) -N- [3- (1-methyl-1 H -pyrazol-4-i) quinoxalin-6-yl] ethan-1, 2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof. Processes for the preparation of said compositions. Use of said compositions for the manufacture of a medicament for the prophylaxis of, or the treatment, in particular the treatment, of diseases, e.g. Cancer. Claim 3: The use according to claim 1 or 2, wherein the formaldehyde scrubber is meglumine.

ARP160100355A 2015-02-10 2016-02-10 USE OF A FORMALDEHYDE CLEANER IN A PHARMACEUTICAL COMPOSITION AR103645A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15154554 2015-02-10

Publications (1)

Publication Number Publication Date
AR103645A1 true AR103645A1 (en) 2017-05-24

Family

ID=52544292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100355A AR103645A1 (en) 2015-02-10 2016-02-10 USE OF A FORMALDEHYDE CLEANER IN A PHARMACEUTICAL COMPOSITION

Country Status (1)

Country Link
AR (1) AR103645A1 (en)

Similar Documents

Publication Publication Date Title
NI201700101A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING N - (3, 5 - DIMETOXIPHENIL) - N'- (1-METHYLETHYL) - N - [3- (1-METHYL-1H-PIRAZOL-4-IL) QUINOXALINE-6-IL] ETHANE-1 , 2-DIAMINE
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
CL2017000379A1 (en) Pyrrolopyrimidine compounds used as toll receptor agonists. 7 (tlr7)
ECSP17007538A (en) 2- (MORFOLIN-4-IL) -1,7-NAPHTHYRIDINES
CL2021002963A1 (en) Novel crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for cancer treatment
CO2018005842A2 (en) Pharmaceutical composition comprising a potent urat 1 inhibitor
BR112017010439A2 (en) compound, pharmaceutical composition, pharmaceutical combination, kit, methods for controlling a fungal disease in a plant and for preventing or treating fungal disease in an individual, and, using a compound
EA201591541A1 (en) BETA SECRETASE INHIBITORS 1 (BACE 1)
AR077139A1 (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT VCH
CO2021010493A2 (en) Halo-allylamine compounds and their use
JOP20210338A1 (en) Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide
CO2023013050A2 (en) Psilocybin compositions, methods of preparing them and methods of using them
ECSP19044591A (en) AROMATIC AMIDES OF CARBOXYLIC ACID AS ANTAGONISTS OF THE B1 RECEPTOR OF BRADIQUININ
CL2012003341A1 (en) Pharmaceutical composition for oral administration comprising bendamustine or an ester, a salt or a solvate thereof, and an excipient which is a non-ionic and hydrophilic surfactant; pharmaceutical combination; and its use for the treatment of chronic lymphocytic leukemia and multiple myeloma, among other diseases.
AR064543A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
AR115913A1 (en) BIO AVAILABLE ORAL DOSAGE FORMS, USE, METHODS
AR103645A1 (en) USE OF A FORMALDEHYDE CLEANER IN A PHARMACEUTICAL COMPOSITION
CL2021000627A1 (en) Pharmaceutical compositions suitable for joint release and their use in the treatment of joint pain
AR108792A1 (en) COMPOSITIONS THAT INCLUDE TIMOLOL
AR083780A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT HCV INFECTIONS
ES2680418R1 (en) Use of a compound in the manufacture of a medicament useful for the treatment by activation of the expression of the CIRP protein of a disease and composition
AR082967A1 (en) FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD
EA201791798A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING N- (3,5-DIMETOXIPHENYL) -N '- (1-METHYLETHYL) -N- [3- (1-METHYL-1H-PYRAZOL-4-IL) CHINOXALIN-6-IL] ETAN-1 , 2-DIAMOND
AR100621A1 (en) INHIBITOR COMPOSITE OF PHOSFOINOSÍTIDO-3-QUINASA d, PHARMACEUTICAL COMPOSITION, USE, METHOD
IN2013MU02286A (en)